{
    "clinical_study": {
        "@rank": "74089", 
        "arm_group": {
            "arm_group_label": "Cyclophosphamide + TBI + BMT", 
            "arm_group_type": "Experimental", 
            "description": "TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die. Combining chemotherapy with bone marrow transplantation may\n      allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in\n      treating patients with chronic lymphocytic leukemia."
        }, 
        "brief_title": "Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "June 2002", 
            "@type": "Actual"
        }, 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: Examine the potential role for high dose cyclophosphamide, total body\n      irradiation and bone marrow transplantation for patients with chronic lymphocytic leukemia\n      who are at high risk for disease progression.\n\n      OUTLINE: Patients receive daily intravenous infusions of cyclophosphamide for two days,\n      followed by total body irradiation in four daily exposures. After completion of the total\n      body irradiation, allogeneic or autologous bone marrow is infused intravenously.\n\n      PROJECTED ACCRUAL: 50 patients are expected to be accrued."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Chronic lymphocytic leukemia (CLL) patients after initial relapse\n        who have achieved a complete or partial remission with fludarabine therapy or after\n        initial relapse or progression Prolymphocytic leukemia in first remission or after relapse\n        Patients 15-65 years old who lack an HLA-identical sibling are eligible for autologous BM\n        transplantation Patients 16-50 years old with an HLA identical or one antigen mismatched\n        related donor are eligible for allogeneic BM transplantation\n\n        PATIENT CHARACTERISTICS: Age: 15-65 (See Disease Characteristics) Performance status:\n        Zubrod no more than 2 Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5\n        mg/dL Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: Cardiac ejection\n        fraction at least 50% Pulmonary: DLCO at least 50% of predicted Other: No severe\n        concomitant medical or psychiatric illnesses\n\n        PRIOR CONCURRENT THERAPY: No extensive prior radiotherapy which would prevent\n        administration of total body radiation Patients may also participate in study MDA-DM-92082\n        for retroviral gene marking of the autologous marrow and blood cells"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002844", 
            "org_study_id": "DM90-106", 
            "secondary_id": [
                "P30CA016672", 
                "MDA-DM-90106", 
                "NCI-G96-1034", 
                "CDR0000065081"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Cyclophosphamide + TBI + BMT", 
                "description": "Daily intravenous infusions of cyclophosphamide for two days,", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cytoxan", 
                    "Neosar"
                ]
            }, 
            {
                "arm_group_label": "Cyclophosphamide + TBI + BMT", 
                "description": "After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.", 
                "intervention_name": "Allogeneic Bone Marrow Transplantation", 
                "intervention_type": "Procedure", 
                "other_name": "Stem Cell Transplant"
            }, 
            {
                "arm_group_label": "Cyclophosphamide + TBI + BMT", 
                "description": "After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.", 
                "intervention_name": "Autologous Bone Marrow Transplantation", 
                "intervention_type": "Procedure", 
                "other_name": "Stem Cell Transplant"
            }, 
            {
                "arm_group_label": "Cyclophosphamide + TBI + BMT", 
                "description": "Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.", 
                "intervention_name": "Total Body Irradiation (TBI)", 
                "intervention_type": "Radiation", 
                "other_name": "radiation therapy"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cyclophosphamide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "refractory chronic lymphocytic leukemia", 
            "Cyclophosphamide", 
            "Cytoxan", 
            "Neosar", 
            "Bone Marrow Transplantation", 
            "total body irradiation", 
            "chronic lymphocytic leukemia", 
            "allogeneic", 
            "autologous"
        ], 
        "lastchanged_date": "July 27, 2012", 
        "link": [
            {
                "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
                "url": "http://cancer.gov/clinicaltrials/MDA-DM-90106"
            }, 
            {
                "description": "UT MD Anderson Cancer Center Website", 
                "url": "http://www.mdanderson.org"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "University of Texas - MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Bone Marrow Transplantation for Chronic Lymphocytic Leukemia", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Richard E. Champlin, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2000", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Effectiveness of high dose cyclophosphamide, total body irradiation and bone marrow transplantation for chronic lymphocytic leukemia", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002844"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 1991", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "University of Texas - MD Anderson Cancer Center": "29.76 -95.369"
    }
}